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Current possibilities of chronic heart failure treatment with positive impact on patient
prognosis interfere with the pathophysiological processes of myocardial remodeling.
RAAS-inhibitors and beta-blockers are considered to be effective pharmacological ther-
apeutics. Available non-pharmacological methods of intervention are cardiac resynchro-
nization therapy, valvular diseases corrections and mechanical cardiac support devices.
The effect of pharmacological therapy is dose-dependent and the effect of all mentioned
treatment methods is additive.
& 2013 Published by Elsevier Urban & Partner Sp.z o.o. on behalf of The Czech Society of
Cardiology.
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Chronic heart failure (CHF) has a signiﬁcant negative impact
on patients' quality of life and prognosis. This point of view
has not changed over the last twenty years. The increase
in incidence of heart failure resulting from more effective
treatment of myocardial infarction, population ageing and
better diagnostic possibilities contribute to skepticism. The
colossal success of pharmacological and device therapy of
CHF during last decades remain in the shadow of a growing
problem. In this work we will try to point out how treatment
possibilities with positive impact on mortality affect the
remodeling process of myocardium.2. Pathophysiology of myocardial remodeling
Cardiomyocytes possess vast genetic plasticity which enables
them to respond to different forms of strain. They are post-
natally terminally differentiated cells unable to multiply and
their loss is irreversible. However, the contents of the cell are
renewed regularly. This process takes place “under the pres-
sure” of current circumstances, which allows for effective
pharmacological interventions in myocardial remodeling.
Ventricular remodeling of the heart is a process of struc-
tural changes in myocardium resulting from different kinds
of overload, independent on primary insult and taking part
in disease progression. On macroscopic level hypertrophy
develops (primary pressure overload) and subsequently dila-
tation—concerning mainly the left ventricle (LV) which gains
more spherical form, its walls become thinner and secondary
mitral regurgitation occurs. Hypertrophy alone or together with
dilatation helps to increase the contractility. Most often both of
these mechanisms take part in LV remodeling which leads not
only to modiﬁcation of LV size and shape but also alteration of
biological qualities of cardiomyocytes and their proportion to
non-cardiomyocytes. These changes result from neurohumoral
stimulation of cardiomyocyte membrane receptors. Cardiomyo-
cytes react to overload, oxidative stress, inﬂammation and
circulating neurohormones which trigger complex signal path-
ways leading to gene expression, posttranslational alterations
and modiﬁcation of proteosynthesis. Final cardiomyocyte phe-
notype resembles the fetal one and alterations of gene expres-
sion ﬁt into so called “fetal program of myocardial
reconstruction”. Increased mechanical stress grows with ven-
tricular dilatation and ﬁlling pressure. Hypertrophy (concentric
remodeling) is a compensatory mechanism whose beneﬁt is
eventually exhausted and surpassed. Reduced oxygen supply to
the hypertrophic tissue leads to ischemia, the tissue is prone to
arrhythmias and other structural changes such as loss of
original left ventricular shape, as described above.
Humoral products determining the hypertrophic pheno-
type are represented by angiotensin II, endothelin-1 and
vasopressin which activate Gq protein-coupled receptor. Nor-
adrenaline acts likewise, binding to α1-receptor. Activation of
tyrosine kinase receptors using their translocation to nucleusto affect gene transcription is another mechanism of action.
A typical receptor coupled with this system is a receptor for
ﬁbroblast growth factor. Activation of beta-receptor leads to
hypertrophy partly through increase in intracellular calcium ions
concentration, partly via tyrosine kinase pathway activation.
One of the attributes of failing myocardium is the loss of
cardiomyocytes. Contractile cells perish during myocardial
remodeling by means of necrosis, apoptosis and autophagy.
Necrosis typically follows myocardial infarction, myocarditis,
toxic effect of adriamycin or alcohol. As far as hypertrophic
myocardium is concerned, necrosis occurs due to anoxia
caused by hypertrophic tissue-capillary disproportion. Apop-
tosis is accompanied by transcriptional and translational
activity and production of speciﬁc proteins. After initiation
of apoptosis the cells are cleared off rapidly without inﬂam-
matory reaction. The incidence of apoptosis in advanced heart
failure remains below 1%, therefore the importance of apoptosis
in remodeling process is unclear. Apoptosis of cardiomyocytes is
triggered by wall stress of failing ventricle and catecholamines.
Failing myocardium expresses higher proportion of fetal genes,
causing changes in composition of cardiomyocyte contractile
proteins. V1-isoform of myosin which contains 2 heavy α-chains
with high ATP-ase activity is replaced by fetal form of myosin V3
containing 2 heavy β-chains with low ATP-ase activity. Further-
more, light myosin chains and troponin I- and T-isoforms
undergo modiﬁcation process as well.
Fetal gene program of failing cardiomyocytes affects the
calcium ion transport. Contraction and relaxation of fetal
myocardium depends much more on calcium shift between
extracellular space and cytosol than on calcium exchange
between cytoplasm and sarcoplasmic reticulum.
Metabolic changes are characteristic for an advanced heart
failure. Higher glucose utilization is probably an adaptation
mechanism to lower oxygen supply which corresponds to a
concept of fetal gene expression program. Due to adrenergic
activation the blood concentration of free fatty acids (FFA)
increases, thus deteriorating glucose transportation to muscles
and increases the gluconeogenesis. These changes, together with
systemic inﬂammatory response may result in insulin resis-
tance. Increased level of FFA affects mitochondrial functions as
well. Beta blocker therapy increases the energetic efﬁciency of
failing myocardium, among other things by shifting the meta-
bolism towards oxidation of saccharides.
Modiﬁcation of extracellular matrix (ECM) is another
important part of myocardial remodeling in CHF. The amount
of collagen in ECM is generally increased in heart failure. This
is partly due to myoﬁbroblast stimulation and imbalance
between metalloproteinase activity (MMPs) and their tissue
inhibitors (TIMPs). Higher amounts of collagen reduce the
compliance of remodeled myocardium and its degradation
probably contributes to dilatation of the ventricles. Myoﬁbro-
blasts are long-term persisting ﬁbroblasts which have been
phenotypically transformed; their activity and hence collagen
turnover in myocardium is regulated by renin–angiotensin–
aldosterone system (RAAS) products and ﬁbrogenic cytokines.
Angiotensin II (ANG II) together with aldosterone stimulates
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mediator of myoﬁbroblast proliferation and ECM formation in
failing myocardium; it stimulates production of tissue growth
factor β (TGF β) which in turn supports collagen synthesis. In
ischemic cardiomyopathy cardiomyocyte necrosis caused by
acute coronary thrombosis initiates scar formation, where
collagen type I is mostly involved. Scarring ensures structural
integrity of the tissue after the loss of contractile cells. Fibrosis
process is not completed by formation of localized scar; myoﬁ-
broblasts activated by neurohumoral response produce ﬁbrous
tissue diffusely in whole myocardium. In tissue remodeled as a
result of ischemic insult diffuse perivascular ﬁbrosis, ﬁbrosis of
arterial and arteriolar walls and adjacent interstitial spaces can
be found. In hypertensive disease, it is the higher amount of
collagen I and presence of perivascular and interstitial ﬁbrosis
which sets apart its histological pattern of a pathologic hyper-
trophy caused by extreme increase in afterload from the adaptive
hypertrophy of myocardium in sportsmen. Myocardium in
dilatational phase, such as dilated cardiomyopathy (DCM) is
characterized by collagen degradation which allows for sliding
of cardiomyocytes one over another resulting in mostly parallel
arrangement. MMPS are the mediators of this proteolysis and
their activity is under control of TIMPS. ANG II potentiates the
activity of plasminogen activator inhibitor I (PAI I) leading to
decrease of MMPs activity and acts as a chemoattractant for the
inﬂammatory cells which may in speciﬁc cases take part in ECM
degradation as well. Inﬂammatory cytokines and ROS produced
during ischemia and reperfusion affect the ECM structure as well
[1]. Out of galectin family, galectin -3 plays an important role in
homeostasis of ECM. This mediator of inﬂammatory response
and ﬁbrotization process stimulates migration and phagocytic
activity of macrophages and ﬁbroblast proliferation. It activates
resting ﬁbroblasts to production of ECM components, increases
collagen I production in myocardium. Galectin-3 affects the
collagen degradation through TIMPs [2].3. Treatment of CHF in relation to myocardial
remodeling
All currently accepted treatment strategies of CHF with posi-
tive impact on patient prognosis interfere with the pathophy-Table 1 – Relation between remodeling parameters and morta
Study Active substance Impac
SOLVD treatment Enalapril Yes [3
SAVE Captopril Yes [5
ANZn Carvedilol Trial Carvedilol Yes [7
MERIT-HF Metoprolol Yes [8
CAPRICORN Carvedilol Yes [1
RALES Spironolactone Yes [1
Val-Heft Valsartan Yes [1
PRIME II Ibopamine Worse
OVERTURE Omapatrilat enalapril Identi
ATTACH Inﬂiximab No [20
EARTH Darusentan No [21
EVEREST Tolvaptan No [22
EMPHASIS Eplerenone Yes [2
n ANZ—Australia–New Zealand.siology of myocardial remodeling, thus reducing the left
ventricular size, endsystolic (ESV) and enddiastolic (EDV)
volume and improving the left ventricular systolic function.
This phenomenon has been described as reverse remodeling.
Pharmacotherapy is one of the treatment strategies with
proved positive effect on reverse remodeling (beta-blockers,
angiotensin-converting enzyme inhibitors (ACE-I), AT1 recep-
tor blockers (ARB), spironolactone, eplerenone). Medications
which had not positive impact on myocardial remodeling
did not positively affect the mortality, either (Table 1). Among
non-pharmacological methods, reverse cardiac remodeling
may be induced by resynchronization therapy, implantable
mechanical heart support devices and surgical correction of
selected valvular diseases, particularly aortic stenosis or atrio-
ventricular valvuloplasty.
3.1. Pharmacotherapy
Angiotensin II (ANG II) is a key mediator in harmful long-term
activation. This highly effective vasoconstrictor is mainly
a growth factor and mediator of proliferation. Decline of
its production in patients with CHF via blockage of key
angiotensin-converting enzyme (ACE) by means of ACE inhi-
bitors caused a revolution in pharmacological therapy of CHF.
During the second half of 80's a favorable impact of ACE-I on
overall mortality in CHF was proved by large randomized studies.
Scandinavian study CONSENSUS [26] showed an important
decrease in overall mortality by enalapril in patients in NYHA
IV stage. The effect of enalapril on prognosis and myocardial
remodeling in patients with CHF in NYHA II and III class was
proved in therapeutic part of SOLVD study [3,4]. Positive effect of
ACEI on patients' prognosis after acute myocardial infarction
with LV dysfunction or signs of heart failure is dose-dependent
and similar within whole family of ACE-I [5–7].
Angiotensin II is derived from angiotensin I by the action of
angiotensin converting enzyme (Fig. 1) or in alternative path-
ways.Particularlyachymase-mediatedtissueproductionofAT
II cannot be blocked by ACE-I, on the contrary ACE-I stimulate
itsproduction. Inaddition, elevated level ofbradykininecaused
by ACE-I may lead to adverse effects such as cough, hypoten-
sionandangioneurotic edema (Fig. 2).AT1 receptor antagonists
prevent vasoconstriction; reduce aldosterone production,lity and morbidity in pharmacological studies in CHF.
t on remodeling (Ref.) Impact on mortality and morbidity
] Reduction[4]
] Reduction[6]
] Reduction[7]
] Reduction[9]
0] Reduction[11]
2] Reduction[13]
4] Reduction[15]
ning [16] Increase [17]
cal effect [18] Neutral [19]
] Increase [20]
] Neutral [21]
] Neutral [23]
4] Reduction[25]
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Fig. 1 – Local RAAS. Angiotensin II (ANG II) is derived from angiotensin I (ANG I) by the action of angiotensin converting
enzyme (ACE) or in alternative pathways (katepsin G, chymasis). Effects of ANG II are mediated by receptors AT1 (target of AT1
receptor antagonists) and AT2.
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Fig. 2 – Long-term increased adrenergic activation.
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val study ELITE II [27] showed a comparable impact of losartan
and captopril on overall mortality, sudden death, heart failure
progression and incidence of myocardial infarction. The effect
on remodeling parameters was similar. In VAL-HEFT study
addition of valsartan to current medication led to reduction of
hospitalizations due to heart failure and decreased the prob-
ability of reaching the combined endpoint (death, incidence of
resuscitation, hospitalization for heart failure, administration
of intravenous inotropic agents or vasodilator therapy) [15]. In
patients with NYHA class III and IV valsartan addition to
therapy had the greatest effect on lowering the combined end-
point. Nevertheless,more than 60% of included patients were in
NYHAII class. Thepositive impact on reverseLV remodelingwasvery interesting. Combination therapy of ACE-I and ARB signiﬁ-
cantly improved systolic function of LV and decreased end-
diastolic LV volume [14]. Beneﬁt of combination therapy of
ACE-I and ARB in patients in advanced stage of CHF was
conﬁrmed by CHARM-Added study. More than 75% of included
patients were in NYHA class III and IV [28].
In RESOLVD study the combination of enalapril and
candesartan in patients in NYHA II and III class had stronger
impact on ESD and ESV decrease and increase in LV EF than
therapy with candesartan or enalapril alone. In addition to
that, dose-related effect on reverse remodeling was well
documented [29]. Combination therapy of ACE-I and ARB is
beneﬁcial in patients with short history of symptomatic heart
failure of non-ischemic etiology where reverse remodeling
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indication for this therapy. Patients in more advanced stages
of heart failure beneﬁt from ARB addition probably due to
exhaustion of ACE-I effect, where angiotensin II is synthe-
sized mostly in non-ACE pathway ( the escape phenomenon)
[30]. In combination therapy of ACE-I and ARB meticulous
monitoring of kalemia and renal functions is required.
One of the causes of beneﬁcial effect of aldosterone
antagonist spironolactone on CHF patient prognosis is indeed
its impact on the myocardial ﬁbrosis process which is
mightily stimulated by aldosterone [31]. Aldosterone block-
ade affects ECT changes and secondarily it has an electro-
stabilizing effect. ACE-I and ARB therapy does not ensure
permanent and sufﬁcient reduction of aldosterone serum
level. Diuretic therapy increases the aldosterone level. Mor-
tality study RALES [13] showed that spironolactone as an
aldosterone antagonist administered in dose of 25–50 mg in
patients in NYHA III–IV treated with ACE-I and loop diuretics
or digoxin signiﬁcantly reduced the overall and cardiovascu-
lar mortality in comparison to placebo. It led to decrease in
BNP level and signiﬁcant reverse remodeling [12].
Beneﬁcial effect of aldosterone receptor blockers in treat-
ment of patients after myocardial infarction complicated by
systolic LV dysfunction was conﬁrmed by results of EPHESUS
study [32]; in patients with moderate heart failure by EMPHA-
SIS study [25]. Patients were treated by eplerenone in these
studies. This selective antagonist of aldosterone receptors
blocking only mineralocorticoid receptors led to reduction of
overall mortality and signiﬁcantly lowered the incidence of
sudden cardiac death. Eplerenone in CHF has an important
impact in lowering BNP and markers of collagen synthesis
levels [33], reduces the TNFα level [34] and induces reverse LV
remodeling [24]. As a selective mineralocorticoid, aldosterone
receptor blocker appears more favorable than spironolactone
because of its less adverse effects—it does not cause gyne-
comastia, impotence and oligomenorrhea.
Beta-blockers are essential part of complex pharmacolo-
gical therapy of patients with CHF. Beneﬁcial effect on
prognosis of the non-selective carvedilol [35] and selective
metoprolol [9], bisoprolol [36] and nebivolol [37] has been
proved in patients with mild and moderate heart failure.
COPERNICUS study [38] showed that beta-blockers are safe
and reasonable treatment equally for NYHA IV patients.
Positive impact of beta-blockers on pathophysiology of
myocardial remodeling is shown in Fig. 2. After the initiation
of beta-blocker treatment, at ﬁrst reduction of LV EF occurs,
after one month systolic function starts to improve and after
3 months of treatment it exceeds its initial values. Reverse LV
remodeling occurs after additional 4–12 months [8]. The
extent of reverse remodeling is dose-dependent. In case of
persisting tachycardia even on maximal recommended or
tolerated dose of beta-blocker, ivabradine administration is
indicated in stable patients [39]. Ivabradine selectively and
speciﬁcally inhibits the If current, which controls the sponta-
neous diastolic depolarization in the sinus node that regu-
lates the heart rate. Ivabradine is indicated in chronic heart
failure NYHA class II to IV with systolic dysfunction, in
patients in sinus rhythm and whose heart rate is ≥75 bpm,
in combination with standard therapy including the beta-
blocker at the maximum tolerated dose or when beta-blockertherapy is contraindicated or not tolerated. It should be
emphasized that treatment can be initiated only in stable
patients, and tachycardia must not be due to decompensation.
Ivabradin in echocardiography substudy of the SHIFT trial
caused a slight improvement in LV EF (32.3%79.1 versus
34.7%710.2) and LVESV reduction (123.8 ml755.6 versus
110.8 ml 754.6) after 8 months of treatment [40].
3.2. Cardiac resynchronization therapy
Cardiac resynchronization therapy (CRT) affects prognosis of
CHF patients in NYHA class III or IV and wide QRS complex,
particularly with LBBB [41]. In these advanced stages of CHF,
CRT improves the LV EF, reduces the size of LV, reduces the
grade of mitral regurgitation and lowers the levels of
biomarkers. REVERSE study [42] did not show any difference
in incidence of clinical deterioration of heart failure during 12
months in patients with NYHA I–II and QRS≥120 ms; anyway,
it had a clear impact on cardiac remodeling. The improve-
ment of endsystolic and enddiastolic LV volume and LV EF
was the strongest in patients with non-ischemic etiology of
CHF and QRS complex wider than 152 ms. In these patients
CRT prolonged time to ﬁrst hospitalization for decompensa-
tion. These results indicate that resynchronization therapy in
moderate stages of heart failure combined with optimal
pharmacological therapy leads to reverse myocardial remo-
deling and may delay decompensation. Assuming that LV EF
is an important prognostic factor, an extrapolation can be
made that reverse remodeling in patients with DCM and LBBB
should lead to decrease in mortality in long-term view. Our
experience shows that CRT enables further titration of beta-
blocker and RAAS-inﬂuencing medications.
3.3. Valvular diseases corrections
Valvular regurgitation may be the primary cause of myocar-
dial remodeling and the subsequent occurrence of chronic
heart failure. Myocardium responds to a volume overload by
parallel replication of sarcomeres, dilatation of ventricle, the
rise of enddiastolic volume and ﬁlling pressure. The cardiac
output is primarily reduced by regurgitation fraction.
On the other hand, signiﬁcant mitral regurgitation (MR) as a
result of left ventricular remodeling accompanies heart failure
at 35–50% [43]. “Functional” MR results from the tethering of
the mitral valve leaﬂets due to ventricular remodeling. Con-
tractile dysfunction alone does not result in signiﬁcant MR. The
presence of signiﬁcant MR is associated with an increasing
mortality among patients with chronic heart failure and
further exacerbates the process of remodeling.
It is necessary to mention that so far there is no randomized
prospective trial of mitral valve surgery compared with a
medical therapy in patients with severe MR and an advanced
heart failure. The retrospective observational analyses reported
statistically signiﬁcant reverse remodeling and improvements
in functional class and quality of life after mitral valve surgery
among carefully selected patients with advanced heart failure.
An important role to induce reverse remodeling of the myo-
cardium plays the valve repair as opposed to valve replace-
ment, which is associated with the poor prognosis. Mitral valve
repair due to nonischemic MR in Acorn trial [44] led among
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to a signiﬁcant reverse remodeling. The 30 days mortality was
1.6% and 2 years survival 85.2%. CorCap device added to mitral
valve repair did not affect MR grade. Patients with severe LV
enlargement (LVEDD ≥80mm), PVO2 ≤13ml/kg/min, systolic BP
≤80mmHg, HF duration ≥8 years, atrial ﬁbrilation, prior cardiac
surgery, renal failure and kachexia were excluded.
Patients considered for mitral valve surgery should be on a
proper medical therapy, all suitable candidates with LBBB
should undergo CRT. Effect of treatment and degree of MR
should be reassessed and prognosis, viability and periopera-
tive risk should be considered carefully.
Catheter correction of mitral regurgitation by Mitra-Clip
leads to relief of symptoms of heart failure and reverse
remodeling of the myocardium. The procedure is successful
in the case of a suitable valve morphology and an experi-
enced interventional cardiologist.
Aortic stenosis is a typical example of a pressure overload
with a subsequent development of ventricular remodeling.
Myocardium reacts to a pressure overload by parallel replica-
tion of sarcomeres, there is a concentric hypertrophy of the
myocardium with an impaired diastolic function. The muscle
mass and perfusion capacity mismatch leads to inadequate
oxygen supply to cardiomyocytes. In this case the loss of
contractile elements occurs due to a combined mechanism
involved in both ischemia and secondly apoptosis in which is
induced by neurohumoral activation. Myocyte loss and pro-
gressive myocardial ﬁbrosis gradually lead to eccentric hyper-
trophy of the myocardium, ventricle dilatation, systolic
dysfunction with a decreased ejection fraction. The ﬁnal
macroscopic shape of the ventricle is identical to that in
dilated cardiomyopathy. Increasing degree of myocardial
ﬁbrosis is associated with the progressive reduction in survi-
val even in patients with good systolic function of LV who do
not have symptoms [45].
Aortic valve replacement (AVR) remains the most effective
treatment even in the case of the presence of LV dilatation
and severe systolic dysfunction. It should be emphasized that
all operated patients must be further treated with farm-
acotherapy in proper doses. In high-risk patients comes into
consideration transarterial aortic valve implantation. In the
case of a low gradient aortic stenosis with severe LV systolic
dysfunction it is essential to exclude primary myocardial
disease.
Delicate problem is the indication of aortic valve replacement
in the case of signiﬁcant aortic regurgitation and severe left
ventricular dilatation and systolic dysfunction. The procedure
can be considered rather as a bridge to heart transplantation.
3.4. Left ventricular assist devices
Implantation of left-ventricular assist devices (LVAD) leads to
hemodynamic and subsequently neurohumoral changes
which signiﬁcantly affect the remodeling process in the
myocardium. Increase in cardiac output and lowering of
cardiac wall stress are the most important factors lowering
the neurohumoral activation. Changes in gene expression
determine the increase in beta-receptors density and sensi-
tivity in myocardium [46], improvement of intracellular
calcium exchange efﬁcacy [47–49], changes in geneexpression for cytoskeletal proteins and integrins [50]. Myo-
cardial specimens after VAD implantation show reduction of
cardiomyocyte size and decrease in collagen content in
absolute majority of cases [51]. While gene expression
changes, ultrastructure and myocardial metabolism following
LVAD implantation are present very often, certain degree of
reverse remodeling at a macroscopic level has been described in
less than one third of cases. Reduction of cardiac chambers size
and improvement of contractile function to such extent which
would allow an LVAD explantation can be expected in 10% of
cases at maximum, according to the majority of relevant pub-
lications. Combination of LVAD implantation together with
intensive pharmacological therapy is a prerequisite for improve-
ment of myocardial systolic function. RAAS blockade is particu-
larly important. Increase in angiotensin II concentration in
myocardium with following ﬁbrosis and increase in myocardial
muscle stiffness occurs in long-term after LVAD implantation
[52]. When considering the possibility of restitution of cardiac
function in patients after LVAD implantation, especially in cases
of fulminant myocarditis or relatively short-lasting CHF in DCM,
early administration and titration of ACE-I, ARB and spironolac-
tone is required [53]. Application of clenbuterol following the
maximal standard pharmacotherapy in patients with non-
ischemic heart failure on LVAD was published. In the frame of
this hareﬁeld protocol this β2-selective agonist was used due to
its anabolic effect on skeletal muscles and myocardium [54].
Clenbuterol induces the so-called “physiological hypertrophy”
without increasing the ﬁbrous tissue content in myocardium.
The efﬁcacy of standard pharmacotherapy in combination with
clenbuterol remains unclear. As a prevention of cardiomyocyte
atrophy while relieving the left ventricle it is important to adjust
the pump regime in the sense of maximal reduction of rotation
frequency along with the clinical status of the patient and
echocardiographic ﬁndings.
Patients on LVAD tolerate medication aimed at CHF better
than patients in very advanced stages of CHF without LVAD.
Symptomatic hypotension and renal function impairment
are often limiting factors in advanced stages of heart failure.4. Conclusion
Inﬂuencing the myocardial remodeling at both ultrastructural
and macroscopic level is the key to improving prognosis of
patients with CHF. The effect of all medications aimed at
reverse remodeling induction is dose-dependent and addi-
tive. Categorical imperative of CHF treatment in all stages
independently on its etiology is the fastest possible introduc-
tion of combination therapy and titration of efﬁcient drugs to
recommended doses.
CRT represents a non-pharmacological treatment of
CHF leading to reverse myocardial remodeling in indicated cases
[55] and often enabling the intensiﬁcation of pharmacotherapy.
LVAD implantation together with pharmacological therapy
leads to restitution of cardiac function and therefore to
possibility of its explantation only in exceptional cases.
Miniaturization of mechanical cardiac support devices,
possibility of transcatheter implantation and perhaps transcu-
taneous energy recharge could in future broaden indications
for patients in whom reverse remodeling can be expected but
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stages of the disease. Equally, CRT implantation is currently
indicated in patients with relatively short history of non-
ischemic heart failure with LBBB in whom titration of phar-
macotherapy is not possible. This method is very successful in
inducing the reverse myocardial remodeling.
Valve surgery is the only causative surgical intervention in
myocardial remodeling; in case of atrioventricular valve it is
essential to preserve the native valve.
Individual approach to patients and their maximal aware-
ness and cooperation is the prerequisite for successful therapy.
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